Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling
M. Mirzaie, E. Gholizadeh, J. J. Miettinen, T. Ruokoranta, F. Ianevski, J. Saarela, M. Manninen, S. Miettinen, C. A. Heckman, M. Jafari
This paper identifies effective and low-toxicity drug combinations for AML using a bipartite network model and patient-derived data, finding ruxolitinib-ulixertinib and sapanisertib-LY3009120 as the most synergistic.
bioRxiv · May 25, 2023Cancer Biology